The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.
UCC April 2020
Advances in genomic testing will help determine lines of therapy in men with mCSPC and mCRPC, according to Raoul S. Concepcion, MD.
Systemic and intravesical therapies are changing the landscape of BCG-unresponsive disease, according to Matthew Galsky, MD.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
